By Sheeba M. | Weedstock Market Intelligence | Friday, October 2, 2026
Cannabis equities enter the final trading session of October’s first week with investors locked on the DEA rescheduling timeline and the Q4 280E relief trade dominating institutional flows. Friday carries extra weight as portfolio managers finalize weekly positioning before the weekend.
Morning Market Setup — Friday, October 2, 2026
Curaleaf Holdings (CURLF) is holding near the $2.85–$2.90 range after a week of measured gains, supported by Q3 earnings expectations showing improved EBITDA margins in Florida and New York core markets. The retail consolidation strategy — closing underperforming dispensaries, doubling down on high-traffic urban locations — appears to be generating the operational leverage bulls have argued for. Check the cannabis stock tracker for live CURLF pricing and volume data.
Green Thumb Industries (GTBIF) remains the strongest balance sheet play in the MSO space heading into Q4. With minimal debt maturities before 2028 and six consecutive quarters of positive free cash flow, GTBIF is well-positioned to weather any DEA timeline delays. Pre-market bids around $9.40–$9.55, with options activity signaling traders are bracing for potential volatility around any regulatory announcement.
Verano Holdings (VRNOF) is a standout performer this week — up approximately 8% since Monday on renewed M&A consolidation speculation. Verano’s Illinois and New Jersey operations generate strong cash flow, and disciplined capital allocation has drawn institutional attention as both a potential acquirer and acquisition target in a post-rescheduling wave. The weedstock tracker shows VRNOF momentum building into the weekly close.
DEA Rescheduling: October Catalyst Window Remains Open
The sector’s forward-looking thesis rests on the DEA’s pending final rescheduling rule under the Controlled Substances Act. With the comment period closed and the DEA under bipartisan Congressional pressure, market participants treat October as the most likely window for a formal announcement. Rescheduling from Schedule I to Schedule III eliminates the 280E tax burden — a change analysts estimate adds $50–$150M annually in after-tax cash flow for the largest MSOs.
Forward-looking note: If the DEA rule publishes in October–November, expect a sharp sector re-rating as Q3 earnings begin incorporating 280E relief into forward guidance. The spread between current valuations and rescheduling-adjusted valuations remains historically wide — significant upside for patient capital. Not financial advice; cannabis stocks are highly speculative.
Friday Trading Themes to Watch
- MSOS ETF flows: AdvisorShares Pure US Cannabis ETF (MSOS) is the institutional sentiment barometer. Unusual volume divergence signals large positioning changes.
- Options expiry: Friday options expiry creates gamma-driven volatility in thinly traded cannabis names. CURLF and GTBIF have the deepest OTC options markets.
- Weekend headline risk: Political developments or federal agency statements over the weekend can gap stocks significantly on Monday’s open.
- Short interest dynamics: Several mid-cap names carry significant short interest relative to float. A DEA headline could trigger cascading short squeezes.
Sector Snapshot — Q4 Entry Points
For investors evaluating Q4 entry points, the risk/reward calculus has rarely looked more favorable on fundamentals while simultaneously carrying more headline risk than at almost any point in the sector’s public market history. The DEA catalyst, 280E relief, and ongoing state expansion (Ohio adult-use ramping; Pennsylvania legalization a major wildcard) create a mosaic of catalysts that, if realized, could drive the sector to multi-year highs. Track all major movers at the Weedstock cannabis stock tracker.
Weedstock Market Intelligence provides cannabis sector analysis for informational purposes only. Nothing here constitutes investment advice. Cannabis stocks are highly speculative; consult a licensed financial advisor before investing.